A5081268224- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- Genomic variations and chromosomal abnormalities
- Childhood Cancer Survivors' Quality of Life
- Eosinophilic Disorders and Syndromes
- Cancer-related Molecular Pathways
- Prenatal Screening and Diagnostics
- Cancer therapeutics and mechanisms
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Hematopoietic Stem Cell Transplantation
- Genetics and Neurodevelopmental Disorders
- Antioxidant Activity and Oxidative Stress
- Lung Cancer Treatments and Mutations
- Advanced biosensing and bioanalysis techniques
- PI3K/AKT/mTOR signaling in cancer
- Immunodeficiency and Autoimmune Disorders
- Bone and Joint Diseases
Advanced Centre for Treatment, Research and Education in Cancer
2018-2024
Tata Memorial Hospital
2017-2024
Homi Bhabha National Institute
2020-2024
HistoGenetics (United States)
2014
Abstract The use of pediatrics-inspired protocols in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) results superior survival compared with the protocols. Pediatrics-inspired carry an increased risk toxicity treatment-related mortality low resource settings, which can offset potential benefits. We studied outcomes prognostic factors treatment AYA ALL a regimen. retrieved data regarding demographics, investigations, details, toxicities from electronic medical records...
The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying therapeutic options for AML patients who progress on therapy, we studied clinical-stage CDK7 inhibitor XL102, which being evaluated solid tumors (NCT04726332).To determine anti-proliferative effects performed experiments including time-resolved fluorescence resonance energy transfer, target...
ABSTRACT Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%–3% of all leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their long‐term effects on growth and bone health in children. We prospectively studied treatment‐free remission (TFR) 45 children with pCML phase imatinib. Eligibility criteria were as per current NCCN guidelines, less stringent qPCR monitoring scheduled every 3 months. TFR was...
Summary Tyrosine kinase inhibitors (TKIs) have drastically improved the outcomes of pCML (paediatric CML) but data on long‐term off‐target toxicities TKIs in children are scarce. In this single‐centre, retrospective cum prospective study chronic phase, we report our experience treating 173 with imatinib and following them for toxicities. Mean (SD) time to attain CHR, CCyR MMR were 3.05 (2.1), 10.6 (8.4) 43.4 (31.8) months respectively. DMR was not attained 59 (34%) patients at last...
The Pediatric Hematolymphoid Disease Management Group (PHL-DMG) at a tertiary cancer care hospital developed extensive patient support programs to improve retention and outcomes while focusing on protocols adapted meet needs. An audit of measures was done for 7-year period from January 2010 December 2016.DMG activities over the study were documented audited. Data retrieved internal databases records. Measures taken their impact assessed by descriptive analytical tools. Survival calculated...
Abstract The expression of CD20 in precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with poor outcomes. addition rituximab to intensive chemotherapy CD20+ ALL has led improved outcomes several studies. However, there no clear evidence regarding the optimal number doses and its benefit without an allogeneic stem cell transplant. Achieving measurable residual disease (MRD)-negative status postinduction would reduce requirement for a Novel approaches are needed induce higher...
Abstract Circulating tumor plasma cells (CTPCs) provide a noninvasive alternative for measuring burden in newly diagnosed multiple myeloma (NDMM). Moreover, measurable residual disease (MRD) assessment peripheral blood (PBMRD) can an ideal to bone marrow MRD, which is limited by its painful nature and technical challenges. However, the clinical significance of PBMRD NDMM still remains uncertain. Additionally, data on CTPC patients not treated with transplant are scarce. We prospectively...
Atypical breakpoints and variant APL cases involving alternative chromosomal aberrations are seen in a small subset of acute promyelocytic leukemia (APL) patients. Over seven different partner genes for RARA have been described. Although rare, these variants prove to be diagnostic challenge require combination advanced cytogenetic molecular techniques accurate characterization. Heterogeneity occurs not only at the level but also clinico-pathological influencing treatment response outcome. In...
Inconclusive knowledge persists regarding the course of chronic myeloid leukemia-chronic phase (CML-CP) patients with detectable abnormal blasts by flow-cytometry at diagnosis. The 2016 WHO classification is not specific sub-classification CML <10% B-lymphoid (ABLB), and suggests these often show rapid progression. We report clinical pediatric CML-CP who had baseline.Retrospective audit all between January 2013 December 2017 were included. Their presentation, demographic profile, treatment...
Pediatric core binding factor acute myeloid leukemia (CBF-AML), although considered a favorable risk subtype, exhibits variable outcomes primarily driven by additional genetic abnormalities, such as KIT mutations.In this study, we examined the prognostic impact of mutations in 130 pediatric patients with CBF-AML, treated uniformly at single center over 4 years (2017-2021). were detected via next-generation sequencing using panel comprising 52 genes for most patients.Our findings revealed...
At a Tertiary Genetic Centre, children with mental retardation (MR) (also referred as intellectualdisability) and associated developmental disabilities were investigated for genetic diagnosis which is important inprevention counseling while offering the risk of recurrence to family. A prospective retrospectivecytogenetic study was conducted on 1760 MR cases chromosomal abnormalities using routine GTG highresolution banding methods karyotyping. Out cases, 555 showed abnormal...
Abstract Introduction Many new markers are being evaluated to increase the sensitivity and applicability of multicolor flow cytometry (MFC)‐based measurable residual disease (MRD) monitoring. However, most studies limited childhood B‐cell lymphoblastic leukemia/lymphoma (B‐ALL), reports in adult B‐ALL extremely scarce small cohorts. We studied expression CD304/neuropilin‐1 a large cohort patients its practical utility MFC‐based MRD analysis. Methods CD304 was blasts from normal precursor B...
Chromosomal translocations have been reported in a number of women undergoing cytogenetic studies for amenorrhoea and gonadal dysgenesis. This study was taken up to emphasize the role X chromosome know frequency X-autosomal with Indian population. Cytogenetic analysis carried out 1567 subjects referred during period 2002–2012. GTG-banding performed from peripheral blood lymphocyte cultures detect abnormalities all cases. The karyotype results revealed 43.6% cases chromosomal (n = 683 cases)....
World Health Organization states the importance of conventional cytogenetics and FISH in hematological malignancy for accurate diagnosis, treatment monitoring response to therapy. Most probes, however, are Analyte- Specific reagents (not FDA approved) thus an elaborate validation procedure prior diagnostic use becomes essential. This study focuses on validating probes by assessing analyte- sensitivity, specificity, accuracy, precision determining normal reference ranges (cut-offs). Eight...
Abstract A new understanding of acute myeloid leukemia as a varied group unique biologic entity has emerged, result the identification various chromosomal aberrations and their association with clinical prognosis diagnosis. Following induction treatment, cytogenetic examination can establish presence any residual malignant cells, it's recurrence, clonal evolution if any, or formation novel abnormalities. The G-banded karyotype been gold standard method for detecting all these years. capacity...
B-cell acute lymphoblastic leukemia (B-ALL) is a heterogeneous disease wherein cytogenetics comprises an independent prognostic factor. Cytogenetic subgroups like B-ALL with t(9;22), MLL rearrangement, hypodiploidy, and Ph-like ALL are stratified as high-risk treated on the regimen. However, subset that does not fall into specific cytogenetic risk groups, classified NOS (Not Otherwise Specified) might receive suboptimal chemotherapy. Identifying genetic abnormalities susceptible to targeted...